Similarities in the immunoglobulin response and VH gene usage in rhesus monkeys and humans exposed to porcine hepatocytes

BMC Immunology

Volumn 7, Issue , 2006, Pages

  Zahorsky Reeves, Joanne L ^a   Gregory, Clare R ^b   Cramer, Donald V ^a   Patanwala, Insiyyah Y ^a   Kyles, Andrew E ^b   Borie, Dominic C ^c   Kearns Jonker, Mary K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CELL ANTIBODY; COMPLEMENTARY DNA; EPITOPE; GALACTOSE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; PENTASACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BIOARTIFICIAL LIVER; CELL ISOLATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENETIC CODE; GENETIC SCREENING; GERM LINE; HUMAN; LEUKOCYTE; LIVER CELL; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; POSTOPERATIVE PERIOD; PROTEIN FAMILY; RHESUS MONKEY; STEM CELL; SWINE; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, HETEROPHILE; CONSENSUS SEQUENCE; DNA; GALACTOSE; GENE EXPRESSION; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HEPATOCYTES; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LIVER TRANSPLANTATION; MACACA MULATTA; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, NUCLEIC ACID; SWINE;

EID: 33646202586     PISSN: 14712172     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-7-3     Document Type: Article

References (48)

1. Samstein B, Platt JL: Physiologic and immunologic hurdles to xenotransplantation. J Am Soc Nephrol 2001, 12:182-193.
2. Cooper DK, Good AH, Koren E: Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immunol 1993, 1:198-205.
3. Galili U, Anaraki F, Thall A, Hill-Black C, Radic M: One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 1993, 82:2485-93.
4. Lin SS, Hanaway MJ, Gonzalez-Stawinski GV, Lau CL, Parker W, Davis RD, Byrne GW, Diamond LE, Logan JS, Platt JL: The role of anti-Gal alpha 1-3Gal antibodies in acute vascular rejection and accommodation of xenografts. Transplantation 2000, 70:1667-74.
5. Stinson EB, Griepp RB, Oyer PE, Shumway NE: Long-term experience with porcine aortic valve xenografts. J Thor Cardiovasc Surgery 1977, 73:54-63.
6. Groth CG, Tibell A, Wennberg L, Korsgren O: Xenoislet transplantation: experimental and clinical aspects. J Mol Med 1999, 77:153-154.
7. Horslen SP, Hammel JM, Fristoe LW, Kangas JA, Collier DS, Sudan DL, Langnas AN, Dixon RS, Prentice ED, Shaw BW Jr, Fox IJ: Extracorporeal liver perfusion using human and pig livers for acute liver failure. Transplantation 2000, 70:1472-78.
8. Pascher A, Sauer IM, Hammer C, Gerlach JC, Nauhaus P: Extracorporeal liver perfusion as hepatic assist in acute liver failure: a review of world experience. Xenotransplantation 2002, 9:309-24.
9. Naruse K, Sakai Y, Guo L, Natori T, Shindoh J, Karasawa. Y, Iida Y, Kojima K, Michishita K, Makuuchi M: Development of a new extracorporeal whole-liver perfusion system. J Artif Organs 2003, 6:211-17.
10. Ueda Y, Iwata H, Paek HJ, Ko IK, Shimooka Y, Katsura N, Ikai I, Yamaoka Y, Ikada Y: Bioartificial liver with whole blood perfusion. ASAIO Journal 2003, 49:401-406.
11. Hui T, Rozga J, Demetriou AA: Bioartificial liver support. J Hepato Pancreat 2001, 8:1-15.
12. Mazariegos GV, Kramer DJ, Lopez RC, Shakil AO, Rosenbloom AJ, DeVera M, Giraldo M, Grogan TA, Zhu Y, Fulmer ML, Amiot BP, Patzer JF: Safety observations in phase 1 clinical evaluation of the Excorp medical bioartificial liver support system after the first four patients. ASAIO Journal 2001, 47:471-75.
13. Mazariegos GV, Patzer JF 2nd, Lopez RC, Giraldo M, Devera ME, Grogan TA, Zhu Y, Fulmer ML, Amiot BP, Kramer DJ: First clinical use of a novel bioartificial liver support system (BLSS). Am J Transplant 2002, 2:260-66.
14. Sauer IM, Kardassis D, Zeillinger K, Pascher A, Gruenwald A, Pless G, Irgang M, Kraemer M, Puhl G, Frank J, Muller AR, Steinmuller T, Denner J, Neuhaus P, Gerlach JC: Clinical extracorporeal hybrid support - phase 1 study with primary porcine liver cells. Xenotransplantation 2003, 10:460-69.
15. Court FG, Wemyss-Holden SA, Dennison AR, Maddern GJ: Bioartificial liver support devices: historical perspectives. ANZ J Surgery 2003, 73:739-48.
16. Baquerizo A, Mhoyan A, Kearns-Jonker M, Arnaout WS, Shackleton C, Busuttil RW, Demetriou AA, Cramer DV: Characterization of human xenoreactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment: an ex vivo model of pig to human xenotransplantation. Transplantation 1999, 67:5-18.
17. H germline progenitors. J Immunol 1999, 163:4399-412.
18. Dehoux JP, de la Parra B, Latinne D, Bazin H, Gianello P: Characterization of baboon anti-porcine IgG antibodies during acute vascular rejection of porcine kidney xenograft. Xenotransplantation 2002, 9:338-349.
19. Wang L, Radic MZ, Galili U: Human anti-Gal heavy chain genes. Preferential use of VH3 and the presence of somatic mutations. J Immunology 1995, 155:1276-1285.
20. Tapinos NI, Polihronis M, Thyphronitis G, Moutsopoulos HM: Characterization of the cysteine-rich secretory protein 3 gene as an early-transcribed gene with a putative role in the pathophysiology of Sjogren's syndrome. Arthritis Rheum 2002, 46:215-222.
21. Segel GB, Woodlock TJ, Xu J, Li L, Felgar RE, Ryan DH, Lichtman MA, Wang N: Early gene activation in chronic leukemic B lymphocytes induced toward a plasma cell phenotype. Blood Cells Mol Dis 2003, 30:27-287.
22. Blouin A, Bolender RP, Weibel ER: Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma: a stereological study. J Cell Biology 1977, 72:441-455.
23. Sandrin MS, McKenzie IF: Gal alpha (1,3) Gal, the major xenoantigen(s) recognized in pigs by human natural antibodies. Immunol Rev 1994, 141:169-190.
24. Tanemura M, Galili U: Differential expression of a-Gal on pig and mouse organs. Transplant Proceed 2000, 32:843.
25. Kearns-Jonker M, Bolger MB, Mencel R, Barteneva N, Starnes VA, Cramer DV: Analysis of contact residues and the binding site configuration of induced xenoantibodies that bind to the gal carbohydrate [abstract]. American Journal of Transplantation 2002, 3:178.
26. Helmuth EF, Letvin NL, Margolin DH: Germline repertoire of the immunoglobulin V(H)3 family in rhesus monkeys. Immunogenetics 2000, 51:519-527.
27. Andris JS, Miller AB, Abraham S, Cunningham S, Roubinet F, Blancher A, Capra JD: Variable region gene segment utilization in rhesus monkey hybridomas producing human red blood cell-specific antibodies: predominance of the VH4 family but not VH4-21 (V4-34). Molecular Immunology 1997, 34:237-253.
28. Teranishi K, Gollackner B, Buhler L, Knosalla. C, Correa L, Down JD, White-Scharf ME, Sachs DH, Awwad M, Cooper DK: Depletion of anti-gal antibodies by intravenous therapy with bovine serum albumin conjugated to gal oligosaccharides. Traansplantation 2002, 73:129-139.
29. Katopodis AG, Warner RG, Duthaler RO, Streiff MB, Bruelisauer A, Kretz O, Dorobek B, Persohn E, Andres H, Schweitzer A, Thoma G, Kinzy W, Quesniaux VF, Cozzi E, Davies HF, Manez R, White D: Removal of anti-Galα 1,3Gal xenoantibodies with an injectable polymer. J Clinical Invest 2002, 110:1869-1877.
30. Karoor S, Molina J, Buchmann CR: Immunoaffinity removal of xenoreactive antibodies using modified dialysis or microfiltration membranes. Biotechnol Bioeng 2003, 81:134-148.
31. Tanemura M, Ogawa H, Yin DP, Chen ZC, DiSesa VJ, Galili U: Elimination of anti-Gal B cells by alpha-Gal ricin 1. Transplantation 2002, 73:1859-1868.
32. McMorrow IM, Buhler L, Treter S, Neethling FA, Alwayn IP, Comrack CA, Kitamura H, Awwad M, DerSimonian H, Cooper DK, Sachs DH, LeGuern C: Modulation of the in vivo primate anti-Gal response through administration of anti-idiotypic antibodies. Xenotransplantation 2002, 9:10-114.
33. Lindeborg E, Kumagai-Braesch M, Tibell A, Moller E: Continued production of xenoimmune antibodies 6-8 years after clinical transplantation of fetal pig islet-like cell-clusters. Xenotransplantation 2001, 8:273-283.
34. Tinguely C, Schaller M, Carrel T, Nydegger UE: Spectrotype analysis and clonal characteristics of human anti-Gal alpha 103Gal antibodies. Xenotransplantation 2002, 9:252-259.
35. Wu GD, Gochi E, Jin Y-S, Swensson J, Starnes VA, Cramer DV: Maturation of xenoantibody gene expression during the humoral immune response of rats to hamster xenografts. Xenotransplantation 2001, 8:291-302.
36. Nozawa S, Xing PX, Wu GD, Gochi E, Kearns-Jonker M, Swensson J, Starnes VA, Sandrin MS, McKenzie IF, Cramer DV: Characteristics of immunoglobulin gene usage of the xenoantibody binding to gal-alpha(1,3)gal target antigens in the gal knockout mouse. Transplantation 2001, 72:147-155.
37. Kearns-Jonker M, Fraiman M, Chu W, Gochi E, Michel J, Wu GD, Cramer DV: Xenoantibodies to pig endothelium are expressed in germline configuration and share a conserved immunoglobulin VH gene structure with antibodies to common infectious agents. Transplantation 1998, 65:1515-1519.
38. Edwards BM, Barash SC, Main SH, Choi GH, Minter R, Ullrich S, Williams E, Du Fou L, Wilton J, Albert VR, Ruben SM, Vaughan TJ: The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein. J Molecular Biology 2003, 334:103-118.
39. Barrios Y, Jirholt P, Ohlin M: Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor. J Molecular Recognition 2004, 17:332-338.
40. Pan J, Naik S, Santangini H, Trenkler D, Jaurugui HO: Flow cytometric characterization of isolated porcine hepatocyte suspensions for liver support. Artificial Organs 1996, 20:1173-1180.
41. Buhler L, Deng S, O'Neil J, Kitamura A, Koulmanda M, Baldi A, Rahier J, Alwayn IP, Appel JZ, Awwad M, Sachs DH, Weir G, Squifflet JP, Cooper DK, Morel P: Adult porcine islet transplantation in baboons treated with conventional immunosuppression or a non-myeloablative regimen and CD154 blockade. Xenotransplantation 2002, 9:3-13.
42. Fujioka H, Cramer DV, Yasunaga. C, Tuso PJ, Wu GD, Middleton Y, Moscioni AD, Rozga J, Demetriou AA, Makowka L: Differential patterns of reaction of human natural antibodies to pig hepatocytes and vascular endothelium. Liver Transpl Surgery 1995, 1:85-93.
43. Shearer MH, Dark RD, Chodosh J, Kennedy RC: Comparison and characterization of immunoglobulin G subclasses among primate species. Clin Diag Lab Immunol 1999, 6:953-958.
44. Calvas P, Apoil P-A, Fortenfant F, Roubinet F, Andris J, Capra D, Blancher A: Characterization of the three immunoglobulin G subclasses of macaques. Scand J Immunol 1999, 49:595-610.
45. Scinicariello F, Engleman CN, Jayashankar L, McClure HM, Attanasio R: Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions. Immunology 2004, 111:66-74.
46. H usage during primary infection of rhesus monkeys with chimeric simian-human immunodeficiency viruses. J Virol 1997, 71:8582-8591.
47. Meek K, Eversole T, Capra JD: Conservation of the most Jh proximal IgVH gene segment (VhVI) throughout primate evolution. J Immunol 1991, 146:2434-2438.
48. Newman R, Alberts J, Carner ADK, Heard C, Norton F, Raab R, Reff M, Shuey S, Hanna N: "Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. BioTechnology 1992, 10:1455-1460.